Revenue: US$84.5m (down 55% from 3Q 2023). Net loss: US$121.3m (loss narrowed by 7.2% from 3Q 2023). US$0.76 loss per share ...

Wall Street's three major indexes closed lower on Tuesday as investors booked some profits from a post-election rally and ...

Richmond Fed President Thomas Barkin said earlier in the day that the U.S. central bank is ready to respond if inflation ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

The latest update is out from Novavax ( (NVAX)). Novavax, a leader in vaccine development, announced the FDA’s removal of a clinical hold on their COVID-19-Influenza combination and influenza vaccine ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

2 strain, prompting the approval of updated versions of the Pfizer and Moderna vaccines targeting that particular strain, and the Novavax vaccine, targeting its parent strain, JN.1, for the 2024 ...

JP Morgan has recently reduced Novavax Inc (NVAX) stock to Underweight rating, as announced on July 30, 2024, according to Finviz. Earlier, on May 10, 2024, JP Morgan had raised the stock from a ...

About a week later, the agency authorized an updated version of Novavax’s protein subunit vaccine for people 12 years and older. The mRNA vaccines specifically target KP.2, a subvariant of JN.

Dr. Marty discusses why the FDA put a hold on the Novavax COVID-Flu vaccines and how their COVID vaccine is different from the others that are offered. She also explains the possible connections ...